Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenzhu Guanxin Fang (SGR) is a traditional Chinese herbal compound medicine primarily investigated by academic institutions such as Guangzhou University of Chinese Medicine and Guangdong Provincial Hospital of Chinese Medicine. It is a multi-herb formulation composed of Radix Ginseng, Rhizoma Atractylodis, Radix Notoginseng, Rhizoma Pinelliae, Hirudo medicinalis, Radix Panacis quinquefolium, and Folium Nelumbinis. Administered as granules, the formulation is designed according to Traditional Chinese Medicine (TCM) principles to enhance qi, accelerate blood circulation, and eliminate intravascular phlegm. It is being evaluated for the treatment of coronary artery disease (CAD), stable angina pectoris, and intermediate coronary lesions, with clinical research focusing on its effects on exercise tolerance, coronary atherosclerosis, and clopidogrel resistance in patients undergoing percutaneous coronary intervention (PCI).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenzhu Guanxin Fang.